No Data
Zhejiang Jianfeng Group (600668.SH): The Shareholder's equity structure of the controlling shareholder has changed.
On January 21, Gelonghui reported that Zhejiang Jianfeng Group (600668.SH) announced that it recently received a notification from the Jinhua Municipal State-owned Assets Supervision and Administration Commission regarding the equity transfer of the company's largest Shareholder, Jinhua Tongji State-owned Assets Investment Co., Ltd. (referred to as "Tongji Investment"). There will be a change in Shareholders of Tongji Investment. According to the document from the Jinhua Municipal Government State-owned Assets Supervision and Administration Commission entitled "Notification Regarding the Equity Transfer of Jinhua Tongji State-owned Assets Investment Co., Ltd.", the Jinhua Municipal State-owned Assets Supervision and Administration Commission has decided to transfer 100% equity of Tongji Investment held by Jinhua State Capital Operation Co., Ltd. (referred to as "State-owned Assets Company").
Zhejiang Jianfeng Group (600668.SH): Jianfeng Dazhan intends to invest 0.997 billion yuan to construct a clinker Cement production line project with a daily output of 4,000 tons.
On January 3, Gelonghui announced that Zhejiang Jianfeng Group (600668.SH) disclosed that its holding subsidiary Yunnan Jianfeng Cement Co., Ltd. (referred to as "Yunnan Jianfeng") plans to invest 997.4772 million yuan to build a clinker cement production line with a daily output of 4,000 tons.
Zhejiang Jianfeng Group (600668.SH) subsidiary Jianfeng Pharmaceuticals passed the on-site inspection by the USA FDA.
Zhejiang Jianfeng Group (600668.SH) announced that its wholly-owned subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (abbreviated as "..."
Zhejiang Jianfeng Group (600668.SH) subsidiary Er Ying Company has obtained the pharmaceutical registration certificate.
The zhejiang jianfeng group (600668.SH) announced that recently, the company's wholly-owned subsidiary zhejiang jianfeng pharmaceutical co., ltd. (abbreviated as...
Zhejiang Jianfeng's Pharmaceutical Arm Gets Nod to Market Diquafosol Sodium Eye Drops
Zhejiang Jianfeng Group (600668.SH): Dioketol sodium eye drops obtained the pharmaceutical registration certificate.
On December 4th, Gelonghui reported that zhejiang jianfeng group (600668.SH) announced that its wholly-owned subsidiary, zhejiang jianfeng pharmaceutical co., ltd., received the Drug Registration Certificate for Diquafosol Sodium Eye Drops issued by the National Medical Products Administration. Diquafosol Sodium Eye Drops are jointly developed by Santen Pharmaceutical Co., Ltd. from japan and Inspire Pharmaceuticals from the usa, used for the treatment of dry eye syndrome, with a specification of 3% (5ml:150mg), since 2010.
There's No Escaping Zhejiang Jianfeng Group Co., Ltd.'s (SHSE:600668) Muted Earnings